Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids

Y. Honda, Y. Kuroki, Eiji Matsuura, H. Nagae, H. Takahashi, T. Akino, S. Abe

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0- fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP- D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.

Original languageEnglish
Pages (from-to)1860-1866
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume152
Issue number6 I
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Pulmonary Surfactant-Associated Protein D
Bronchoalveolar Lavage Fluid
Pulmonary Alveolar Proteinosis
Collagen Diseases
Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases
Serum
Blood Proteins
4 alpha-glucanotransferase
Enzyme-Linked Immunosorbent Assay
Pulmonary Surfactant-Associated Protein A
C-Type Lectins
Mannose-Binding Lectin
Recombinant Proteins
Lung Diseases
Glycoproteins
Healthy Volunteers
Biomarkers
Monoclonal Antibodies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Honda, Y., Kuroki, Y., Matsuura, E., Nagae, H., Takahashi, H., Akino, T., & Abe, S. (1995). Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. American Journal of Respiratory and Critical Care Medicine, 152(6 I), 1860-1866.

Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. / Honda, Y.; Kuroki, Y.; Matsuura, Eiji; Nagae, H.; Takahashi, H.; Akino, T.; Abe, S.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 152, No. 6 I, 1995, p. 1860-1866.

Research output: Contribution to journalArticle

Honda, Y, Kuroki, Y, Matsuura, E, Nagae, H, Takahashi, H, Akino, T & Abe, S 1995, 'Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids', American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 6 I, pp. 1860-1866.
Honda, Y. ; Kuroki, Y. ; Matsuura, Eiji ; Nagae, H. ; Takahashi, H. ; Akino, T. ; Abe, S. / Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. In: American Journal of Respiratory and Critical Care Medicine. 1995 ; Vol. 152, No. 6 I. pp. 1860-1866.
@article{fa760fe3249545bab4b9e35ecdec4875,
title = "Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids",
abstract = "Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0- fold, respectively, of those in healthy volunteers; 91.5{\%} of the patients with IPF, 81.3{\%} with IPCD, and 100{\%} with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP- D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.",
author = "Y. Honda and Y. Kuroki and Eiji Matsuura and H. Nagae and H. Takahashi and T. Akino and S. Abe",
year = "1995",
language = "English",
volume = "152",
pages = "1860--1866",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6 I",

}

TY - JOUR

T1 - Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids

AU - Honda, Y.

AU - Kuroki, Y.

AU - Matsuura, Eiji

AU - Nagae, H.

AU - Takahashi, H.

AU - Akino, T.

AU - Abe, S.

PY - 1995

Y1 - 1995

N2 - Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0- fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP- D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.

AB - Pulmonary surfactant protein D (SP-D) is a hydrophilic glycoprotein with a reduced molecular mass of 43 kDa and a member of the C-type lectin superfamily, along with mannose-binding proteins and surfactant protein A (SP-A). We have recently prepared monoclonal antibodies against human SP-D and developed an enzyme-linked immunosorbent assay (ELISA). In this study, the levels of SP-D in sera and bronchoalveolar lavage (BAL) fluids of patients with lung diseases were determined by ELISA, using human recombinant SP-D as a standard. We demonstrated that the concentrations of SP-D in sera are prominently increased in patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen disease (IPCD), and pulmonary alveolar proteinosis (PAP). Patients with IPF, IPCD, and PAP exhibited levels of serum SP-D 5.1-fold, 7.2-fold, and 7.0- fold, respectively, of those in healthy volunteers; 91.5% of the patients with IPF, 81.3% with IPCD, and 100% with PAP exhibited serum SP-D levels that exceeded the cut-off value (mean + 2 SD of control value). Serum SP-D levels appeared to reflect the disease activity of IPF and IPCD and the disease severity of PAP. High levels of SP- D in BAL fluids were shown in patients with PAP, but not with IPF and IPCD. We conclude that measurement of SP-D in sera can provide an easily identifiable and useful clinical marker for the diagnosis of IPF, IPCD, and PAP, and can predict the disease activity of IPF and IPCD and the disease severity of PAP.

UR - http://www.scopus.com/inward/record.url?scp=0028820752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028820752&partnerID=8YFLogxK

M3 - Article

C2 - 8520747

AN - SCOPUS:0028820752

VL - 152

SP - 1860

EP - 1866

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6 I

ER -